Ventana Medical Systems, Inc.
08/15/2013VENTANA BenchMark Special Stains automation: manual versus automated time-lapse video
VENTANA BenchMark Special Stains automated slide stainer eliminates manual processes and temperature dependencies with automated deparaffinization and independent slide heating for histology labs upgrading manual processes or current automation systems
AZBio
06/24/2013AZBio and SynCardia on ABC15
By: Christina Estes ABC15 Tucson-based SynCardia Systems was among the companies showcased at the annual AZ Bio Expo.It’s a chance for bioscience and technology companies to learn more about funding opportunities and hear success stories.According to the Arizona BioIndustry Association, our state is getting more federal funding for research and seeing higher job growth in the bioscience industry compared to the national average.“Tucson and Arizona are the international headquarters for the world’s only total artificial heart,” said Don Isaacs, SynCardia vice president of communications. “They replace the exact same parts of the heart as if you had a heart transplant.”The SynCardia heart is made in Arizona using bio-compatible material also made here. Isaacs says they have 82 employees in Arizona and about 80 people currently using the heart. The device is considered a bridge for people awaiting a transplant or a life saver for those who will not get transplants due to age or medical conditions.“There’s only 2,200 hearts available per year in the United States and the level of donors has been the same for the last twenty years,” Isaacs said.SynCardia is also undergoing FDA clinical trials for the world’s first wearable power supply for their temporary artificial heart. ©2007 The E.W. Scripps Co. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. (Republished with permission from ABC15) Read more: http://www.abc15.com/dpp/news/region_southeast_valley/tempe/Arizona-company-SynCardia-Systems-makes-worlds-first-total-temporary-artificial-heart#ixzz2X99ewU3x
AZBio Members
05/29/2013Leadership and Capital: Harry A. George
In 2012, Harry A. George, co-founder of Solstice Capital, was named Arizona Bioscience Leader of the Year. Watch his acceptance speech recorded live at the AZBio Awards 2012.
AZBio Members
05/17/20132012 Fast Lane Award Winner - the Critical Path Institute
With both drug development costs and healthcare costs at record heights, how can we drive innovation and lifesaving discoveries down the path faster. That is the question the team at the Critical Path Institute (C-Path) asks every day. Critical Path Institute , a healthcare change agent and leading center of excellence for collaborative scientific innovation, was formed with visionary support from the State of Arizona, UA, Science Foundation Arizona, FDA and the community at large. Its mission: to improve human health and well-being by developing new technologies and methods to accelerate the development and review of medical products. There is no other entity in the country that does what C-Path does. C-Path Milestones and “firsts” include: 1st preclinical safety biomarkers (7) qualified by FDA and its counterparts in Europe and Japan – biomarkers used to detect drug-induced kidney injury earlier and more precisely. 1st CDISC (Clinical Data Interchange Standards Consortium) therapeutic area data standard enables aggregating and easier FDA review of Alzheimer’s clinical trial data. 1st and largest open database of CDISC aggregated Alzheimer’s clinical trial data (6,100 patients, 22 clinical trials) enabling scientists to look for means to detect disease earlier and understand disease progression based on age, sex, genotypes. 1st drug-disease trial model and clinical trial simulation tool submitted/under review by FDA – model enables scientists to better design Alzheimer’s clinical trials. 1st imaging biomarker for trial enrichment qualified by EMA – biomarker used to select patients in very early stages of Alzheimer’s for inclusion in clinical trials. C-Path brings together stakeholders to create what no one company, university, or government agency could do alone: 6 global consortia with 1,000 scientists, 41 companies, government agencies, patient groups, and academia to collaborate on “tools” to help drug development and focus on drug safety, drug effectiveness, diseases of the brain, developing new imaging biomarkers, and testing drug combinations. C-Path’s collaborative work is just beginning to translate knowledge of disease and human physiology into safe and effective therapies.
AZBio Members
05/17/2013Pediatric Neuroscience
Dr. Adelson has been recognized as one of the foremost experts on pediatric head injury , lecturing around the United States and the world. Now he joined Phoenix Children's to expand a program that surpasses the typical model of pediatric care. For some, it's playing a musical instrument. For others, it's painting. But for P. David Adelson, MD, FACS, FAAP, the director of the Hospital's Barrow Neurological Institute and chief of neurosurgery, his passion is a bit atypical. "My hobby is neuroscience," he says. "The heart's a pump, the kidney's a filter – those are all simple functions which are there to support who we are and what we do." But the brain controls it all, he says. "I just looked at the brain and neurosciences as the next frontier; studying something of which I would never get bored." Dr. Adelson has been recognized as one of the foremost experts on pediatric head injury clinical management, lecturing around the United States and the world. He has been published in numerous medical and scientific journals defining "state-of-the art" in the care of children with traumatic brain injuries. The path to Phoenix Children's Hospital Dr. Adelson came to Phoenix in January from Pittsburgh, where he served as the A. Leland Albright Endowed Professor of Neurosurgery/Pediatric Neurosurgery at Children's Hospital of Pittsburgh and Vice Chairman, (Research) at the University of Pittsburgh School of Medicine , one of the most prominent neurosurgical departments in the country.
AZBio Members
06/06/2013DNA on a Shirt
DNA on a SHIRT is an innovative, unique company that created wearable and wallable™ genetic art that couples art and science, meshing fashion and education in the process. Through their various DNA inspired T-shirts and art prints, our mission is to create a catalyst for engagement by engaging art, science and people. Our products include art pieces and T-shirts that showcase the DNA fingerprint of people, pets, plants and zoo animals.